Hims & Hers Health (NYSE:HIMS) Posts Quarterly Earnings Results, Misses Estimates By $0.03 EPS

Hims & Hers Health (NYSE:HIMS) issued its earnings results on Monday. The company reported $0.03 earnings per share for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.03), FiscalAI reports. The business had revenue of $890.37 million for the quarter, compared to the consensus estimate of $893.13 million. Hims & Hers Health had a negative return on equity of 9.62% and a negative net margin of 6.65%. Hims & Hers Health’s revenue for the quarter was up 48.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.06 EPS.

Here are the key takeaways from Hims & Hers Health’s conference call:

• Revenue grew 49% year over year to $890 million, accelerating for a second consecutive quarter; domestic revenue growth also improved to 21%. Adjusted EBITDA was $82 million, and the company generated $26 million of free cash flow.
• Subscribers fell by 100,000 sequentially to 2.8 million, which management attributed largely to deliberately lower U.S. weight-loss marketing and international brand migrations. The company expects subscriber headwinds to continue in Q4, with growth recovery anticipated after marketing ramps up in Q1.
• Hims & Hers lowered its 2026 Adjusted EBITDA guidance to $257 million–$277 million and expects Q4 revenue growth to slow to 42%–45%. Gross margin declined about seven percentage points sequentially to 57%, primarily due to a greater mix of lower-margin branded weight-loss products internationally.
• The company is expanding weight-loss options through Lilly and Novo partnerships, and raised its 2026 international revenue expectation to at least $650 million. Management says the AI-native experience reached 70% of weight-loss subscribers and users send four times as many messages, though these investments and broader international marketing may weigh on near-term results.
• Hims & Hers plans to launch Peptides+ later this month and recently expanded injectable and oral testosterone offerings, using its own pharmacy and lab infrastructure. Peptide revenue is not expected to be material in Q4, and some planned products depend on regulatory clarity.

Hims & Hers Health Stock Performance

HIMS traded up $1.73 during midday trading on Wednesday, hitting $20.86. 23,622,758 shares of the company traded hands, compared to its average volume of 14,708,043. The firm has a market capitalization of $4.87 billion, a PE ratio of -25.13 and a beta of 2.53. The company’s 50-day moving average is $27.95 and its 200 day moving average is $26.80. Hims & Hers Health has a 52 week low of $13.74 and a 52 week high of $40.99. The company has a quick ratio of 0.87, a current ratio of 0.92 and a debt-to-equity ratio of 3.85.

Latest Hims & Hers Health News

Here’s some of the latest news about HIMS:

• Positive Sentiment: Revenue rose 49% year over year to $890.4 million, and international revenue grew sharply. The growth offers a bright spot, although acquisitions contributed to expansion and profitability weakened. Article: Hims & Hers: 3 Key Takeaways for Long-Term Investors
• Neutral Sentiment: The company appointed Andrew Huberman to its board and has discussed offering peptides, which could support its growth strategy but do not resolve near-term concerns around margins, demand or regulation. Article: Hims & Hers Announces Andrew Huberman as Director
• Negative Sentiment: Management lowered its 2026 adjusted EBITDA outlook to $257 million–$277 million, and fourth-quarter revenue guidance of $875 million–$895 million came in well below analysts’ expectations. The cut adds to concerns about the company’s earnings trajectory. Article: Hims & Hers Cuts 2026 Earnings Outlook

Insider Transactions at Hims & Hers Health

In other news, insider Deborah M. Autor sold 16,773 shares of the stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $27.85, for a total value of $467,128.05. Following the completion of the sale, the insider directly owned 48,961 shares of the company’s stock, valued at $1,363,563.85. This represents a 25.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Soleil Boughton sold 25,111 shares of the stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $27.55, for a total value of $691,808.05. Following the sale, the insider owned 313,964 shares of the company’s stock, valued at $8,649,708.20. This represents a 7.41% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 133,905 shares of company stock valued at $3,826,977. Company insiders own 11.76% of the company’s stock.

Analyst Ratings Changes

HIMS has been the subject of a number of research reports. Jefferies Financial Group cut their price target on shares of Hims & Hers Health from $31.00 to $24.00 and set a “hold” rating for the company in a research note on Tuesday. Deutsche Bank boosted their target price on Hims & Hers Health from $25.00 to $26.00 and gave the company a “hold” rating in a research note on Tuesday, August 11th. Weiss Ratings reiterated a “sell (d)” rating on shares of Hims & Hers Health in a research report on Wednesday, November 4th. TD Cowen increased their price objective on Hims & Hers Health from $25.00 to $30.00 and gave the company a “hold” rating in a research note on Tuesday, August 11th. Finally, Wall Street Zen raised shares of Hims & Hers Health from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Three analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Hims & Hers Health currently has a consensus rating of “Hold” and an average target price of $31.53.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc. operates a consumer-focused telehealth platform that connects patients with licensed healthcare providers and offers access to treatments and wellness products. Its services include online consultations, prescription care and over-the-counter products. The company serves a range of health needs, including hair loss, sexual health, skin care, mental health and weight management. Its platform also offers primary care and other services, with offerings varying by location and individual eligibility.